ADMA NASDAQ
ADMA Biologics, Inc.
1W: -0.5%
1M: -22.7%
3M: -47.5%
YTD: -52.7%
1Y: -58.6%
3Y: +107.3%
5Y: +391.9%
$8.24
-0.22 (-2.60%)
Weekly Expected Move ±9.6%
$7
$7
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (24h)
2
Hourly Sentiment (24h)
-0.64
Bearish
1 bullish
0 neutral
6 bearish
Articles (7d)
7
Daily Sentiment (7 Days)
Articles (100)
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
ADMA Securities Investigation: ADMA Biologics 29% Stock Drop Triggers Securities Fraud Investigation Over Channel Stuffing Claims – Investors Urged to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA Fraud Notice: ADMA Biologics is being Investigated for Securities Fraud after 29% Stock Drop -- Investors Reminded to Contact BFA Law
ADMA Shareholder News: ADMA Biologics Investigated for Securities Fraud Over Alleged Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
New Strong Sell Stocks for May 14th
$ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
New Strong Sell Stocks for May 11th
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
$ADMA Investor News: ADMA Biologics Stock Drops 29% Amid Channel Stuffing Claims Triggering Securities Fraud Investigation – Contact BFA Law if You Suffered Losses
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Adma projects 2026 revenue of $530M-$560M and withdraws longer-term guidance amid standard IG dislocation
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses
ADMA (ADMA) Q1 2026 Earnings Transcript
12 Health Care Stocks Moving In Wednesday's After-Market Session
Earnings Scheduled For May 6, 2026
Here are the major earnings after the close Wednesday
$ADMA Shareholder News: ADMA Biologics 29% Stock Drop Leads to Securities Fraud Investigation – BFA Law Encourages Investors with Losses to Act
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Investor Notice: ADMA Biologics (NASDAQ:ADMA) may have Committed Securities Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law about the Pending Investigation
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know
Summers Value Fund adds TBPH, exits ADMA among Q1 moves
$ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
ADMA Stock: ADMA Biologics Securities Fraud Investigation is Ongoing – Investors with Losses Urged to Contact BFA Law
Calamos Advisors LLC Increases Stock Position in ADMA Biologics Inc $ADMA
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends
ADMA Legal Notification: ADMA Biologics Securities Class Action Investigation Ongoing – Investors with Losses after 29% Stock Drop Notified to Contact BFA Law
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
$ADMA Investigation: BFA Law Notifies ADMA Biologics Investors that Lost Money after 29% Stock Drop of Ongoing Securities Fraud Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NVO's Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Stock Notification: ADMA Biologics (NASDAQ:ADMA) Securities Fraud Investigation Over Channel Stuffing Claims is Ongoing – Contact BFA Law if You Lost Money
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
$ADMA Investigation Reminder: ADMA Biologics Investors are Reminded to Contact BFA Law after Company Investigated for Securities Fraud Over Channel Stuffing Claims
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. (NASDAQ:ADMA) Investors to Contact the Firm Regarding Ongoing Investigation
Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
ADMA Investor Announcement: ADMA Biologics Investigated After Channel Stuffing Claims Cause 29% Stock Drop – Investors with Losses Notified to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
ADMA Biologics Inc $ADMA Stock Holdings Lessened by Aberdeen Group plc
Allspring Global Investments Holdings LLC Decreases Stock Position in ADMA Biologics Inc $ADMA
$ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA Law
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Option Care Health and Nexstar Media are the most oversold among U.S. mid-cap stocks
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
$ADMA Securities Alert: ADMA Biologics Investigated for Securities Fraud over Culper Research Report Revelation – Investors with Losses Urged to Contact BFA Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
$ADMA Investor News: ADMA Biologics Faces Securities Fraud Investigation after Culper Research Revelation Leads to 29% Stock Drop – BFA Law Notifies Investors to Act
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
Novartis Bolsters Immunology Pipeline With Excellergy Deal
12 Health Care Stocks Moving In Friday's Intraday Session
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Biggest stock movers Friday: Crypto stocks, U, VERI, and more
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday
ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand
ADMA Biologics gains after refuting short seller claims
12 Health Care Stocks Moving In Friday's Pre-Market Session
$ADMA Shareholders: ADMA Biologics Hit with Securities Fraud Investigation After Stock Slides 29% Amid Channel Stuffing Claims – Investors with Losses Alerted to Contact BFA Law
SRPT Stock Surges on Promising Early Results From siRNA Programs